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Abstract
Purpose: To validate the performance of a respiratory gating system for the automated
delivery of the deep inspiration breath-hold (DIBH) technique.
Methods: The gating system utilized an automatic gating interface (Elekta Response)
which connected a marker-based respiratory motion monitoring system to the linear accelerator
control system. The gating system was characterized dosimetrically and temporally using two
distinct approaches. Central-axis output and energy constancy were evaluated across 8 beammatched linear accelerators. Additionally, a representative set of 5 treatment plans were delivered
both non-gated and gated to a 2D diode array (MapCHECK). The respiratory motion monitoring
system optically tracked a reflective marker that was attached to a dynamic phantom (QUASAR).
The phantom was programmed to replicate a typical DIBH breathing waveform. The passing rates
between these modes of operation were evaluated using gamma analysis and a percent dose
difference comparison. Modular and end-to-end approaches were used to quantify system
latencies. The modular components evaluated were the streaming latency of the tracking camera,
sampling rate of the tracking software, signal travel time, and latency of the linear accelerator. The
end-to-end approach involved measuring the displacement of a target moving at known velocities
during the during the gating process.
Results: Output and energy constancy were both within ± 0.5% for each beam energy and
linear accelerator investigated. The average differences in passing rates between non-gated and
gated modes of operation were within ± 0.4% using gamma analysis (2%, 1mm). Average passing
rates between modes of operation were greater than 99% using a percent dose difference
comparison (1%). The first gated segment was found to have significantly (p =.02) longer beam-

vii

on latency compared to the subsequent gated segment. End-to-end beam-on and beam-off latency
for the subsequent gated segment was found to be 1.49 and 0.34 seconds, respectively, which was
consistent with measured component totals.
Conclusion: The gating system was able to achieve dosimetric operating characteristics
that are desirable for accurate delivery of the DIBH technique. The methodology presented can be
generalized to other respiratory gating systems that utilize the automatic gating interface studied
in this work.
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Chapter 1. Introduction
1.1.

Background and Significance

1.1.1. Patient Motion
Radiation therapy for cancer treatment uses ionizing radiation to destroy or damage
cancerous cells within the body. The goal is to deliver a tumoricidal dose to the target volume
while also minimizing the radiation toxicity to the surrounding healthy tissues. To achieve this
goal, personalized treatment plans are created for each patient. The treatment planning process
begins with a radiation therapy treatment simulation. During simulation, images are taken of the
patient to obtain a representation of their anatomy in the treatment position at a particular point in
time. Immobilization devices are often used during simulation and treatment delivery to ensure a
reproducible setup and limit the patient’s movement throughout imaging and treatment. The
planning images obtained during treatment simulation are typically acquired via helical computed
tomography (CT) and reconstructed to create a 3D image set of the patient. The image set is used
to design the custom treatment plan with the assumption that the planning images will accurately
represent the patient’s anatomy throughout the course of treatment.
Patient motion that occurs during treatment simulation can cause artifacts in the CT images
used to plan the patient’s treatment. In general, a CT artifact refers to any systematic discrepancy
between the CT numbers in the reconstructed image and the true attenuation coefficients of the
imaged anatomy (Tsai et al., 2011). Motion artifacts are a specific type of CT artifact which result
from the CT reconstruction algorithm’s assumption that the patient’s anatomy will be stationary
during image acquisition (Keall et al., 2006). Motion artifacts can appear as blurring, streaking or
a distortion of the imaged anatomy, as shown in Figure 1.1. Ultimately, motion artifacts that are
present in the images used for treatment planning can affect the accuracy of the dose calculation
or can make it difficult to delineate critical anatomic structures when designing the plan (Balter et
1

al., 1996). Typically, safety margins are added to critical structures during treatment planning to
account for their positional uncertainty due to patient motion (Landberg et al., 1999). Choosing
the appropriate margins to apply to these structures can be difficult if significant patient motion
occurred during treatment simulation because of the resulting motion artifacts that can present in
the planning images (Keall et al., 2006).

Figure 1.1. From (Keall et al., 2006), thoracic CT images of the same patient acquired during (a)
free breathing (b) exhale to reduce respiratory motion during image acquisition. If not accounted
for, patient motion that occurs during image acquisition can cause motion artifacts in the
reconstructed images.
Separate from its ability to produce motion artifacts during treatment simulation, patient
motion can also impact treatment delivery by causing a material change in the patient’s anatomy
or geometric arrangement relative to how the treatment was planned. Interfraction motion refers
to changes that occur between treatment fractions which typically result from the finite ability to
perfectly reproduce the treatment position. Deviations in the patient’s anatomy or positioning
relative to the planning CT have been shown to cause systematic dose delivery errors (Erridge et
al., 2003). If significant interfraction changes are observed, a new treatment plan can be created to
account for the anatomic changes that have occurred.

2

In contrast, intrafraction motion is any movement that occurs during the treatment fraction
and could be the result of the respiratory, skeletal muscular, cardiac, or gastrointestinal motion
(Keall et al., 2006). Respiratory motion in particular has been shown to affect all tumor sites in the
thorax and abdomen and is the most extensively studied cause of intrafraction motion in radiation
therapy (Keall et al., 2006). Respiratory motion presents challenges, especially for advanced
techniques like intensity modulated radiation therapy (IMRT), which seeks to deliver highly
conformal radiation doses to the target volume using relatively tight margins to spare the
surrounding healthy tissues (Brandner et al., 2017). In the presence of respiratory-induced tumor
motion these margins may need to be expanded to ensure that the target volume receives adequate
dose coverage. However, simply increasing these margins to account for the full range of tumor
motion isn’t always feasible as it can lead to excessive healthy tissue exposure.
Previous work has shown that respiratory-induced tumor motion can vary widely between
patients and that the magnitude of this motion is not predictable by the tumor’s size, its location,
or the patient’s pulmonary function (Stevens et al., 2001). Therefore, it is recommended that tumor
motion be assessed prior to treatment if respiratory induced-tumor motion is expected (Keall et
al., 2006). Imaging studies are often used to quantify the magnitude of respiratory motion. CT
scans acquired at inhale and exhale can define the range of tumor motion in three dimensions and
fluoroscopy studies have been used to observe two-dimensional anatomic motion with respect to
time (Malone et al., 2000). Another technique, known as four-dimensional computed tomography
(4DCT), provides a compromise between the time resolution of fluoroscopy and the 3D spatial
resolution of a CT study. 4DCT correlates the CT scan with the patient’s breathing so that image
sets can be reconstructed at particular phases or amplitudes of the respiratory cycle. If an imaging
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study shows respiratory-induced tumor motion that exceeds 5 millimeters (mm) it is recommended
that methods be employed to manage the patients respiratory motion (Keall et al., 2006).
The goal of respiratory motion management is to mitigate the effects of respiration on the
radiation therapy process. Motion encompassing methods accomplish this by increasing the
margins around the target volume to account for the full range of respiratory motion. Forced
shallow breathing techniques seek to limit the amplitude of respiration through compression of the
patient’s abdomen with a ridged frame. Real-time tumor-tracking methods continuously reposition
the radiation beam to follow the path of the target volume. Additionally, there are several motion
management methods that utilize beam gating. Beam gating is a broad term used in radiation
therapy to describe treatments that synchronize delivery of the radiation beam to a particular stage
of the patient’s breathing cycle, referred to as the gating window (Saito et al., 2018). Free-breathe
respiratory gating is a specific type of beam gating in which the patient’s treatment is delivered at
preselected phases or amplitudes of their natural breathing cycle. Free-breathe respiratory gating
can decrease the range of target motion while the beam is being delivered, potentially reducing the
needed margins around the target volume (Keall et al., 2002). Each of these respiratory motion
management methods are illustrated in Figure 1.2.
1.1.2. Deep Inspiration Breath-Hold
Deep inspiration breath-hold (DIBH) is another respiratory motion management method
used in radiation therapy which utilizes beam gating. The DIBH technique involves delivery of
the patient’s treatment while they are holding their breath at deep inspiration and has been shown
to offer improved efficiency when compared to free-breathe respiratory gating (Berson et al.,
2004). Typically, the patient will hold their breath for approximately 15-25 seconds while the beam
is delivered. Then, treatment delivery is paused, allowing the patient to breathe freely until they
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are ready to begin the next DIBH. This process is repeated until the treatment fraction is fully
delivered.
There are two major benefits derived from the DIBH technique. The first major benefit is
that DIBH can create a more favorable anatomical arrangement for treatment of certain disease
sites. During deep inspiration, the heart is displaced posteriorly, inferiorly, and medially, as
depicted in Figure 1.3. For the treatment of left-sided breast cancer, this displacement can reduce
the radiation dose that the heart receives throughout the course of treatment (Pedersen et al., 2004).
This is especially beneficial because major coronary events have been shown to increase linearly
with the mean dose to the heart by 7.4% per gray (Darby et al., 2013). Therefore, the DIBH
technique provides a valuable tool to reduce the likelihood of major coronary events later in life
for patient’s receiving radiation therapy for left-sided breast cancer.

Figure 1.2. From (Choi and Seong, 2018), illustrating various respiratory motion management
methods used in radiation therapy: (A) motion encompassing methods (B) breath-hold (C) forced
shallow breathing (D) free-breathe respiratory gating (E) real-time tumor tracking.
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The other major benefit of the DIBH technique is the reduction in respiratory motion that
occurs during a breath-hold. Often times this technique is employed for the treatment of thoracic
tumors, such as lung cancer, to reduce tumor motion during delivery. The reduction in tumor
motion allows for decreased margins around the target volume which can reduce the radiation
exposure to the surrounding healthy tissues (Hanley et al., 1999). While left-sided breast and lung
are among the most common treatment sites that employ the DIBH technique, a variety of other
sites such as the liver and pancreas have also been shown to benefit from the respiratory motion
mitigation derived from this technique (Zeng et al., 2019; Dawson et al., 2001).

Figure 1.3. From (Wiant et al., 2015), heart contours during free-breathing (purple), partial
inspiration (turquoise), and deep inspiration breath-hold (yellow). Axial, sagittal, and coronal
views of the same patient are shown from left to right. During deep inspiration, the heart is
displaced posteriorly, inferiorly, and medially relative to its position during free breathing.
Treatments that utilize DIBH are planned using an image set acquired during treatment
simulation with the patient in the breath-hold position. Typically, audio or visual feedback is used
to synchronize the helical CT scan with the DIBH so that image acquisition only occurs while the
patient is in the DIBH position (Keall et al., 2006). Throughout treatment simulation, a respiratory
motion monitoring system is typically used to display a respiratory trace of the patient. The
amplitude of the respiratory trace should be within a predefined range during each DIBH to ensure
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that the image set acquired during treatment simulation will adequately represent the patient’s
anatomy when they are performing a DIBH during treatment.
The treatment position used during simulation is reproduced prior to each fraction of
treatment and a respiratory motion monitoring system is typically used to demonstrate that
patient’s respiratory trace during each DIBH is consistent with the amplitude levels used during
treatment simulation. Once the patient’s respiratory trace enters the predefined amplitude range,
the radiation beam is activated, either manually by the therapist or automatically if the linear
accelerator is equipped with an interface that connects the respiratory motion monitoring system
to the linear accelerator control system. This implementation of the DIBH technique has the
advantage of constant respiratory monitoring which allows the beam to be paused, or held,
automatically, should the patient exit the breath-hold position prematurely.
One of the most widely studied respiratory motion monitoring systems used in radiation
therapy is an abdominal marker-based optical tracking system (Real-Time Position Management,
Varian Medical Systems, Palo Alto, CA). The system utilizes an infrared camera to track a
reflective external marker typically placed on the patient’s abdominal surface; the marker’s
displacement is used as the surrogate for the patient’s respiratory motion. This system relies on the
assumption that internal tumor motion will correlate with the motion of the external marker
surrogate throughout the course of treatment (Ionascu et al., 2007). Previous works have shown
that tumor motion can be correlated well with the motion of an external marker placed on the
patient’s abdominal surface (Beddar et al., 2007; Vedam et al., 2003; Gierga et al., 2005).
However, interfraction changes in the tumor-surrogate relationship have been observed, therefore
it is recommended that the tumor is imaged directly throughout the course of treatment to verify
the accuracy of this relationship (Hoisak et al., 2004). One of the major benefits of the abdominal
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marker as a respiratory motion surrogate is that they can be used for the majority of radiation
therapy patients because of their non-invasive nature (Keall et al., 2006).
1.1.3. Automatic Gating Interface
Recently, an automatic gating interface has been commercially released by a major linear
accelerator manufacturer (Response, Elekta Oncology Systems, Stockholm, Sweden) that is
capable of automating the delivery of the DIBH technique. The gating interface utilizes a digital
relay inserted into the linear accelerator’s Pulse Repetition Frequency (PRF) interlock chain to
perform the automated beam gating (Evans et al., 2010). When the PRF relay is open, pulses of
radiation cannot be generated, causing a beam-hold. Third party respiratory motion monitoring
systems can be used to generate the binary gating signal which triggers the gating interface to open
or close the digital relay at the appropriate times during gated treatment deliveries.
1.1.4. Dosimetric Considerations
Saito et al. (2018) validated the gating interface for use with a commercially available
respiratory motion monitoring system (Abches, APEX Medical Inc, Tokyo, Japan). To help
establish dosimetric accuracy, they measured central-axis output and beam energy with and
without the use of beam gating. Gated measurements utilized beam-on durations ranging from 1.1
to 7 seconds and beam-holds of 2 seconds in between each beam-on period. For both output and
beam energy, the percentage difference of the gated measurements relative to non-gated
measurements was found to be less than 1%.
Freislederer et al. (2015) used the gating interface to investigate the impact that the duty
cycle had on the accuracy of gated treatment deliveries. The duty cycle refers to the percentage of
time that the radiation beam is on during treatment delivery. Their results showed that the dose
difference between gated and non-gated deliveries increased when low duty cycles were utilized.
Previous work has shown that the transient temperature of the electron gun filament and magnetron
8

can cause unstable beam production upon start-up (Fujimoto et al., 2013). One of the risks of beam
gating with low duty cycles is the increase in the amount of start-up processes that occur during a
treatment delivery, negatively impacting dosimetric accuracy. However, for duty cycles of at least
30%, the differences in dose delivery for static open fields were found to be less than 1%
(Freislederer et al., 2015).
Noto et al. (2014) assessed the accuracy of delivering volumetric modulated arc therapy
(VMAT) treatment plans in multiple gated segments to simulate the DIBH technique. A gated
segment refers to the portion of the treatment that is delivered in between each beam-hold during
a gated treatment delivery. Each plan was delivered with gated segment durations ranging from 10
to 40 seconds and beam-holds of 5 seconds in between each gated segment. In this study, they
manually pushed the start and interrupt buttons to deliver and hold the beam, respectively. They
found that the dose delivery was stable and accurate when the gated segment durations were 15
seconds or greater. However, the manual beam gating performed in this study may not adequately
replicate the operating characteristics encountered with use of an automated gating interface.
Jermoumi et al. (2017) used a linear accelerator (Elekta Synergy, Elekta Oncology
Systems, Stockholm, Sweden) that was equipped with the gating interface to study the impact of
automated beam gating on delivery accuracy. This study delivered two separate stereotactic body
radiation therapy (SBRT) treatment plans using a variety of beam-on and beam-off durations
during delivery. One combination in particular was intended to simulate the DIBH technique and
involved beam-on durations of 12 seconds followed by beam-holds of 6 seconds after each beamon period. These gated treatment deliveries exhibited passing rates of 100% using gamma analysis
with a passing criteria of (1%, 1mm). Their work has shown that the gating interface is capable of
facilitating the accurate delivery of gated SBRT treatments. However, they may not have used
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beam-holds that were long enough to be representative of the DIBH technique that their work was
investigating.
1.1.5. Temporal Considerations
Another important characteristic to assess when validating the performance of a system
used for automated beam gating is latency. Beam-on or beam-off latency refer to the time delay
that occurs prior to beam start-up or a beam-hold, respectively. Beam-on latency can decrease the
efficiency of treatment delivery by reducing the number of monitor units (MU) that can be
delivered during each gated segment. Beam-on latency is especially of concern for systems
intended for free-breathe respiratory gating as time delays prior to beam start-up can exceed the
short gating windows that are often utilized with this type of beam gating. In this case, the patient’s
respiratory surrogate would exit the gating window before beam delivery can begin. Alternatively,
beam-off latency can result in the patient’s respiratory surrogate exiting the gating window before
the beam is held, which could lead to a geometric miss of the target (Smith and Becker, 2009).
Snyder et al. (2017) quantified both beam-on and beam-off latencies using a linear
accelerator (Elekta Versa HD, Elekta Oncology Systems, Stockholm, Sweden) equipped with the
gating interface and a commercially available respiratory motion monitoring system (AZ-733VI,
Anzai Medical Systems, Tokyo, Japan). This work used the electronic portal imaging device
(EPID) mounted on the linear accelerator to capture images of a ball bearing phantom. The EPID
is a flat panel detector that can record exposures using the linear accelerator’s therapeutic MV
beam. Reference images were acquired with the phantom kept stationary at predefined amplitudes.
Experimental images were also collected with the phantom moving at known velocities and set to
trigger at the same amplitudes used for the reference images. The displacement of the ball bearing
between the reference and experimental images was divided by its known velocity to calculate the
beam-on and beam-off latencies.
10

Woods and Rong (2015) used a similar approach as Snyder et al. (2017) to quantify latency.
In their work, the average temporal delay was found by plotting the measured positional
displacements against the known target velocities. The slope of a linear fit line was used to quantify
the end-to-end latencies of the system. They argued that using a linear fit is more accurate than
averaging the time delay calculated at each velocity, because low velocity data points may be
largely affected by the measurement uncertainty and the size of pixels in the images used to
measure the displacements.
Saito et al. (2018) evaluated latency using a multichannel oscilloscope. This method
allowed for various component latencies of the system including the gating interface and linear
accelerator (Elekta Synergy, Elekta Oncology Systems, Stockholm, Sweden) to be quantified
separately. They observed considerably larger beam-on latency during the first gated segment
compared to subsequent gated segments, as shown in Figure 1.4. Because of the differences they
observed, this study did not include the first gated segment in their analysis. To our knowledge,
no work has investigated the temporal characteristics of both the first and subsequent gated
segments during automated delivery with this gating interface.
1.2.

Research Motivation
Before implementing a system used to facilitate automated beam gating, it is recommended

that a baseline of dosimetric and temporal accuracy be established (Klein et al., 2009). In
particular, systems intended for use with the DIBH technique should be able to deliver the planned
treatment accurately in the presence of extended beam-holds. These extended beam-holds should
not significantly alter important dosimetric characteristics like output or energy. When evaluating
the temporal characteristics of such a system the main concern is the beam-off latency, as time
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delays prior to a beam-hold can pose a safety concern during treatment delivery (Smith and Becker,
2009).
No previous studies have reported on validation of this gating interface for use with an
abdominal marker-based optical tracking system. There are commercially available respiratory
motion monitoring systems that utilize optical tracking, but these systems directly track the
patient’s surface in three dimensions. Currently, there are no systems that are compatible with this
particular gating interface which are designed to optically track an external marker placed on the
patient’s abdominal surface. Historically, most of the knowledge and clinical data regarding
motion monitoring for radiation therapy has utilized optically tracked markers on the patient’s
abdominal surface as the surrogate for respiratory motion. The body of knowledge existing for
these types of respiratory motion monitoring systems provides motivation for their implementation
with this gating interface.

Figure 1.4. From (Saito et al., 2018), system latencies during the (a) first gated segment (b)
subsequent gated segment. Oscilloscope output is shown for the respiratory motion monitoring
system (blue), gating interface (green), and linear accelerator monitor chamber (orange).
12

Woods and Rong (2015) evaluated the performance of a gating system across multiple
linear accelerators (TrueBeam, Varian Medical Systems, Palo Alto, CA). The gating system
studied in their work utilized a similar respiratory motion monitoring system (Real-Time Position
Management, Varian Medical Systems, Palo Alto, CA) as the one studied in this work. However,
they mainly focused on temporal characteristics of the gating system during their validation efforts.
There is motivation to also evaluate the dosimetric aspects of gating performance across multiple
linear accelerators.
The goal of this work was to validate the temporal and dosimetric characteristics of a
respiratory gating system. The gating system consisted of an automatic gating interface that
connected a marker-based respiratory motion monitoring system to the linear accelerator control
system. Dosimetric characteristics were evaluated across multiple linear accelerators to allow for
the intercomparison of its gating performance. Because of the intended clinical use of the gating
system, this work focused on validating the system for automated deliveries that utilize DIBH.
1.3.

Hypothesis and Specific Aims
The hypothesis of this work was that the respiratory gating system can achieve the desired

operating characteristics during automated deliveries that are representative of the DIBH
technique. These operating characteristics include output and energy constancy within 2%, an
average decrease in gamma passing rates between the non-gated and gated modes of operation that
is less than 2%, and end-to-end beam-off latency that is within 300 milliseconds (ms). The three
specific aims used to address this hypothesis are as follows:
Aim 1: Evaluate output and energy constancy using the gating interface to facilitate automated
beam-holds
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Aim 2: Deliver a set of treatment plans to assess delivery accuracy resulting from use of the gating
system
Aim 3: Quantify the end-to-end beam-on and beam-off latency of the gating system as well as the
individual components that contribute to these overall latencies

14

Chapter 2. Methods and Materials
2.1.

Aim 1: Output and Energy Constancy
Central-axis output and beam energy were measured with and without the use of automated

beam-holds. In this work, deliveries with and without the use of automated beam-holds are referred
to as the gated mode of operation and non-gated mode of operation, respectively. Constancy
between these modes of operation was quantified to assess the impact that automated beam-holds
had on these dosimetric quantities.
2.1.1. Gating Control Software
For this aim, gating control software provided by the manufacture (Response Service Tool,
Elekta Oncology Systems, Stockholm, Sweden) was used to generate the binary gating signal. The
software allows the user to create gating cycles with custom beam-on and beam-off combinations
to test the functionality of the gating interface (Jermoumi et al., 2017). To incorporate beam-holds
that were representative of the DIBH technique, a gating cycle was created with a 33 second period
and 70% duty cycle, as shown in Figure 2.1. This gating cycle was looped continuously while
gated measurements of central-axis output and beam energy were collected.

Figure 2.1. Gating control software displaying a gating cycle with a 33 second period and 70%
duty cycle.
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2.1.2. Output
Linear accelerator output was measured along the beam central axis using a PTW 30013
or a PTW 30006 farmer ionization chamber (PTW, Freiburg, Germany). The ionization chamber
was connected to a CNMC model 206 electrometer (CNMC Company Inc., TN, USA) which was
used to measure the charge liberated during each delivery. The raw electrometer reading was
converted to dose to water using protocol recommended by Task Group 51 of the American
Association of Physicists in Medicine (Almond et al., 1999). The resulting dose was divided by
the number of monitor units (MU) delivered to yield the output with units of cGy/MU.
Measurements collected under the non-gated mode of operation were delivered using 100 MU and
those collected under the gated mode of operation were delivered using 600 MU to ensure that
approximately 3-4 beam-holds occurred during each gated measurement. Photon output was
evaluated using reference conditions of 100-centimeter (cm) source-to-axis distance (SAD), 10 cm
depth in solid water, 10x10 cm2 field size at isocenter, and 11 cm of backscatter. Electron output
was evaluated using reference conditions of 100 cm source-to-surface distance (SSD), 2.4 cm
depth in solid water, 10x10 cm2 field size at the surface, and 11 cm of backscatter.
2.1.3. Beam Energy
In this work, a tissue phantom ratio (TPR) was used as the surrogate for photon beam
energy. TPR was calculated using the equation
TPR =

Dd
,
Dd 0

(2.1.)

where Dd is the absorbed dose in a phantom at a depth (d) and Dd0 is the absorbed dose at a
reference depth (d0) with both measurements sharing the same the same source-to-point distance.
TPR was evaluated at a reference depth (d0) of 10 cm and a depth (d) of 5 cm in solid water using
a 10x10 cm2 field size at isocenter.
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A percent depth dose (PDD) was used as the surrogate for electron beam energy. PDD was
calculated using the equation
PDD =

Dd
x 100% ,
Dd 0

(2.2.)

where Dd is the absorbed dose at a depth (d) and Dd0 is the absorbed dose at a reference depth (d0)
with both measurements sharing the same the same SSD. Electron PDD was evaluated at a
reference depth (d0) of 2.4 cm and a depth (d) of 4.1 cm in solid water using a 10x10 cm2 field size
at the surface. Measurements of PDD and TPR both utilized 100 MU for non-gated deliveries and
600 MU for gated deliveries.
2.1.4. Constancy
In this work, constancy was used to quantify the change in central-axis output and beam
energy resulting from the use of automated beam-holds during delivery. Constancy was calculated
using the equation
Constancy =

####### - Nongated
############
Gated
x 100% ,
############
Nongated

(2.3.)

####### and ############
where Gated
Nongated refer to average value of the measurements collected in each mode of
operation.
Output constancy and energy constancy were evaluated on each of the linear accelerators
listed in Table 2.1, which were all beam-matched. For this aim, constancy was evaluated for each
photon energy available on the linear accelerator and a single representative 10 MeV electron
energy. Three measurements of output and beam energy were collected under non-gated and gated
modes of operation for each of the energies utilized. The uncertainty associated with output and
energy constancy was calculated using the equation
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Constancy Uncertainty = $%

#######*δNongated
-100*Gated
############'2
&Nongated

2

2

100*δGated
( +)
* ,
############
Nongated

(2.4.)

where δNongated and δGated represent the standard deviation of the three measurements collected
in each mode of operation. Equation (2.4.) was derived using the general propagation of errors
methodology.
Table 2.1. Linear Accelerators Utilized in this Work

2.2.

Label

Make and Model

Accelerator # 1

Elekta Infinity

Accelerator # 2

Elekta Versa HD

Accelerator # 3

Elekta Infinity

Accelerator # 4

Elekta Infinity

Accelerator # 5

Elekta Infinity

Accelerator # 6

Elekta Infinity

Accelerator # 7

Elekta Infinity

Accelerator # 8

Elekta Synergy

Aim 2: Treatment Delivery Accuracy
Treatment plans from representative anatomic sites were delivered both non-gated and

under conditions that mimicked the DIBH technique, using the gating system to facilitate
automated beam-holds. The treatment delivery accuracy and reproducibility achieved with the
gating system were evaluated using these measurements.
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2.2.1. Gating System
The gating system studied in this work consisted of an automatic gating interface that
connected a respiratory motion monitoring system to the linear accelerator control system. The
respiratory motion monitoring system was created in-house at Mary Bird Perkins Cancer Center
(MBPCC) and was designed to track the displacement of a reflective marker placed on the
appropriate surrogate for respiratory motion. A reflective sphere embedded within the marker was
optically tracked using a complimentary metal-oxide semiconductor (CMOS) camera with a USB
interface.
The respiratory motion monitoring system utilized in-house tracking software to display a
respiratory trace based on the reflective marker’s displacement, as shown in Figure 2.2. The
tracking software was also used to define the position and width of an amplitude-based gating
widow. When the respiratory trace passed through the midline of the amplitude-based gating
window the tracking software would signal to the gating interface to close the digital PRF relay,
allowing beam delivery to begin. Delivery would continue continuously until the respiratory trace
exited the gating window entirely. Then the tracking software would signal to the gating interface
to open the PRF relay, causing an automated beam-hold. This process would repeat throughout the
gated treatment delivery until the treatment fraction was fully delivered.
2.2.2. Dynamic Phantom
A dynamic phantom (Quasar Respiratory Phantom, Modus Medical Devices, Ontario,
Canada), shown in Figure 2.3, was used to simulate the abdominal surface displacement of a
patient undergoing the DIBH technique. This phantom consisted of an acrylic body attached to a
programmable drive unit which could simultaneously move the phantom’s chest wall platform in
the anterior-posterior direction and the phantom’s translation stage in the superior-inferior
direction. Cylindrical inserts of various densities could be attached to the translation stage and
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moved within the phantom’s body, simulating one-dimensional lung and tumor motion. The
phantom could be operated under software control to reproduce one-dimensional motion of
inputted respiratory waveforms.

Figure 2.2. Tracking software used the displacement of a reflective marker to display a respiratory
trace (black). An amplitude-based gating window (red) and window midline (blue) were used as
thresholds to trigger the beam off and on, respectively.

Figure 2.3. Dynamic phantom with chest wall platform, translation stage and attached cylindrical
insert.
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2.2.3. Representative DIBH Waveform
The abdominal displacement of a patient who was previously treated at MBPCC with the
DIBH technique was used to create a representative DIBH breathing waveform. The patient’s
abdominal displacement trace was imported into the phantom’s control software. Using the
software’s wave editor tools, a portion of the trace was selected, which included a breath-hold and
the free-breathe recovery period. This portion of the breathing trace was repeated to produce the
final waveform used in this work, shown in Figure 2.4. The waveform had a breath-hold duration
of approximately 24 seconds and a free-breathe duration of approximately 33 seconds, which are
representative of patients with the DIBH technique.

Figure 2.4. Representative breathing waveform used to simulate the abdominal displacement of a
typical patient undergoing the DIBH technique.
2.2.4. Treatment Plan Set
A set of five treatment plans from representative anatomic sites that commonly employ the
DIBH technique were used to assess the change in delivery accuracy resulting from use of the
gating system. Delivering the same set of treatment plans across all linear accelerators tested
ensured that there was constancy across measurement sets, allowing for the intercomparison of
21

gating performance. The five treatment plans utilized in this work were taken from patients who
were previously treated at MBPCC using the DIBH technique. Included in the set were VMAT
and SBRT cases because gated delivery of these plan types presents challenges for the linear
accelerator to deliver accurately due to varying gantry speeds and dose rates (Snyder et al., 2017).
A 3D conformal radiation therapy (3D-CRT) case for left-side breast cancer was also included in
the set because the DIBH technique is commonly employed for these plan types. Information about
each of the treatment plans included in the set is shown in Table 2.2.
Table 2.2. Treatment Plan Characteristics
Anatomic Site

Treatment Type

Number of Fields

Energy

Total MU

Lung

VMAT

2

6x

425

Chest Wall

VMAT

2

6x

477

Pancreas

VMAT

2

6x

482

Lung

SBRT

2

6x

1934

Left-Sided Breast

3D-CRT

2

6x
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2.2.5. Treatment Plan Delivery
To mimic a typical treatment delivery that employs the DIBH technique, the experimental
setup shown in Figure 2.5 was used to deliver treatment plans in the gated mode of operation. For
these deliveries, the phantom was placed on its side with the chest wall platform removed. This
orientation allowed the translation stage to move in the anterior-posterior direction which reduced
off-axis motion and allowed for greater maximum displacement as discussed by Belanger et al.
(2016). The reflective marker was attached to the translation stage of the phantom and centered on
the treatment couch using the room’s sagittal laser. The phantom was operated under software
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control and programmed to replicate a representative DIBH waveform, mimicking the abdominal
displacement of a typical patient being treated with this technique. The camera used to track the
fiducial maker was also centered using the room’s sagittal laser and positioned 80 cm from the
reflective marker. A two-dimensional diode array (MapCHECK, Sun Nuclear Corporation,
Melbourne, FL, USA) was positioned at isocenter and used to record the incident dose distribution
from each delivery.

Figure 2.5. Experimental setup used for treatment plan delivery. A tracking camera monitored the
displacement of a reflective marker. The reflective marker was able to move in the directions
specified to reproduce a representative DIBH waveform. A two-dimensional diode array at
isocenter recorded the incident dose distribution for each delivery.
In contrast to specific aim 1, where a vendor software tool was used to generate the gating
signal, the respiratory motion monitoring system generated the gating signal during each treatment
delivery in the gated mode of operation. The respiratory motion monitoring system’s tracking
software was calibrated using the known diameter of a reflective sphere embedded within the
marker, which allowed for the width of the gating window to be designated in mm rather than
pixels. In this work, the width of the amplitude-based gating window was approximately 8 mm for
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the VMAT and 3D-CRT breast and thoracic cases and 5 mm for the SBRT thoracic case, which
reflected typical values used clinically at MBPCC.
All treatment plan deliveries were carried out on linear accelerators # 1 through 7 in Table
2.1. Linear accelerator # 8 was not utilized for this aim of the project because the set of treatment
plans were not deliverable on this linear accelerator due to an incompatible linear accelerator head.
Each treatment plan was delivered under non-gated and gated modes of operation to the twodimensional diode array. Typically, 3-6 beam-holds occurred during the delivery of each treatment
plan in the gated mode of operation. The diode array was kept in the same position between nongated and gated deliveries to allow for comparison between these modes of operation. In addition,
the lung VMAT treatment plan was chosen from the set to be delivered 3 separate times under
each mode of operation to assess delivery reproducibility. The dose distribution measured by the
diode array during each delivery was saved and analyzed to assess the delivery accuracy and
reproducibility of the gating system.
2.2.6. Analysis
Measurements of treatment plan deliveries acquired in both modes of operation were
analyzed using commercially available analysis software (SNC Patient, Sun Nuclear Corporation,
Melbourne, FL, USA), shown in Figure 2.6. For each of the treatment plans included in the set, a
planned dose distribution was exported from the treatment planning system (TPS). The planned
dose distribution represents the expected dose profile incident on the diode array during treatment
delivery. Gamma analysis was used to quantify the agreement between the planned and measured
dose distributions. Gamma analysis is a composite metric that takes into account the dose
difference (%) and the distance-to-agreement (DTA) between the points in each distribution (Low
et al., 1998). The percentage of points satisfying the dose difference and DTA gamma criteria is
referred to as the gamma passing rate. In this work, gamma passing rates for each treatment
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delivery were evaluated using gamma criteria of (3% dose difference, 3mm DTA) and (2% dose
difference, 1 mm DTA). To assess the change in delivery accuracy resulting from use of the gating
system, a metric referred to in this work as the passing difference was used. The passing difference
is the difference in gamma passing rates between non-gated and gated deliveries of the same
treatment plan, as shown by the equation
Passing Difference (%) = [NonGated Passing Rate]-[Gated Passing Rate].

(2.5.)

The average passing difference for the set of treatment plans and associated standard error were
calculated for both gamma criteria utilized.

Figure 2.6. Analysis software used to compare the measured dose distribution (left) to the planned
dose distribution (right) using gamma analysis.
A percent dose difference comparison was also used to assess the delivery accuracy of the
gating system. Instead of comparing each measurement to its planned dose distribution, as was
done with gamma analysis, the percent dose difference provided a method for comparing the nongated and gated treatment deliveries directly to one another. This comparison sampled the same
point from each distribution to test whether the two points were within a specified percentage dose
difference of one another. The passing rate from this comparison was calculated for each treatment
plan included in the set using passing criteria of 3% and 1%. Additionally, the average passing rate
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for the set of treatment plans and associated standard error were computed for both passing criteria
utilized.
To assess delivery reproducibility, passing rates for repeat deliveries of the lung VMAT
treatment plan were calculated using gamma analysis with gamma criteria of (3% dose difference,
3mm DTA). The average passing rate and associated standard deviation were calculated for each
mode of operation. The magnitude of the standard deviation for these repeat deliveries was used
to evaluate delivery reproducibility in the non-gated and gated modes of operation.
2.3.

Aim 3: Latency
End-to-end and component latencies were quantified during the first and subsequent gated

segments of automated delivery to evaluate the temporal characteristics of the respiratory gating
system. End-to-end beam-on or beam-off latency refers to the overall time delay associated with
the gating system automatically turning on or off the radiation beam during gated treatment
delivery, respectively. Component latency refers to the time delay of the individual elements of
the gating system that contribute to these end-to-end latencies. The gating system studied in this
work was modular in nature, which means that the latency of the individual components that make
up the system were independent of one another and could be evaluated separately. The summation
of the individual component latencies was compared to the end-to-end measurement to assess the
agreement between these two approaches.
2.3.1. Modular Approach
The modular components that contributed to the latency of the respiratory motion
monitoring system were the streaming latency of the camera used to optically track the reflective
marker surrogate, the sampling rate of the tracking software, and the time it took for the gating
signal generated by the tracking software to travel to the gating interface. Streaming latency
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represents the time it takes for frames captured by the tracking camera to be displayed on a video
monitor. To quantify the tracking camera’s streaming latency, a physical stopwatch was filmed
using the camera. Frames of the stopwatch captured by the tracking camera were displayed on a
video monitor. A separate recording device with a framerate of 120 frames per second (fps) was
used to simultaneously record both the video monitor and the physical stopwatch, as shown in
Figure 2.7. The streaming latency of the separate recording device was negligible because the
physical stopwatch and the video monitor were both included in the same frame. The time
displayed by the physical stopwatch was used as the reference timestamp. The difference between
the reference timestamp and the video monitor timestamp was used to quantify the tracking
camera’s streaming latency. Ten separate frames were used to calculate the average streaming
latency of the tracking camera and associated standard deviation.
The sampling rate of the tracking software represents the frequency at which the software
could update the position of the reflective marker surrogate. The tracking software was designed
to produce log files listing reflective marker’s positions and associated timestamps during use of
the software. The sampling rate of the tracking software was confirmed using these log files. The
difference between 10 successive timestamps within the log file were used to calculate the average
sampling rate and associated standard deviation.
To quantify the travel time of the gating signal from the tracking software to the gating
interface, a software program was created which was capable of triggering the gating signal in the
tracking software at a known time. The gating control software provided the time at which the
gating interface received this gating signal. The difference between the timestamp in the gating
control software and the triggered timestamp was used to quantify the signal’s travel time.
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Figure 2.7. Experimental setup used to quantify the tracking camera’s streaming latency. The
difference between the reference timestamp and the video monitor timestamp was used to quantify
streaming latency.
In addition to the components of the respiratory motion monitoring system, the beam-on
and beam-off latencies of the linear accelerator were also evaluated. In this work, the linear
accelerator beam-on latency was defined as the time between the PRF relay closing and the dose
rate increasing to 80% of its maximum value. Alternatively, the linear accelerator beam-off latency
was defined as the time between the PRF relay opening and the dose rate decreasing to 20% of its
maximum value. These latencies were measured during the first and subsequent gated segments
to investigate changes to the linear accelerator’s temporal characteristics during automated
delivery using the gating interface.
The service graphing feature of the linear accelerator control system was used to observe
the status of the PRF relay and the dose rate of the linear accelerator, simultaneously. The service
graphing feature allows treatment control system variables to be plotted with respect to time on
the same set of axes. Item 44 part 4 was used to observe the dose rate of the linear accelerator and
item 2201 part 190 was used to observe the status of the PRF relay. Values of 0 and 1 for the PRF
relay status corresponded to an open and closed relay state, respectively. The dose rate was scaled
by a factor of 0.01 so that both variables could be viewed clearly on the same set of axes. These
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variables were plotted simultaneously as a function of time to measure the beam-on and beam-off
latencies of the linear accelerator.
Ten separate plots of these two variables were acquired during the first and subsequent
gated segments using accelerator # 2 in Table 2.1. Plots generated during the first gated segment
were collected by initializing beam delivery while the PRF relay was in an open state, which
prevented beam delivery to begin. The service graphing feature was triggered to begin collecting
data and was programmed to stop collecting when the dose rate of the linear accelerator decreased
to zero. Once data collection began, the PRF relay was switched to a closed state using the gating
control software. The beam was delivered for approximately 10 seconds before the PRF relay was
returned to an open state, which caused the service graphing feature to stop data collection.
Plots generated during the subsequent gated segment were acquired by first delivering the
beam for approximately 10 seconds. Then, the PRF relay was switched open using the gating
control software and left in this state for roughly 10 seconds. The 10 second beam-hold duration
was chosen to be representative of the DIBH technique. After this beam-hold, the service graphing
feature was triggered and the beam was delivered with the same procedure used during the first
gated segment. The plots generated from these measurements were used to measure the latencies
of the linear accelerator during the subsequent gated segment.
The beam-on and beam-off latency of the linear accelerator was measured on each plot
generated. Because of the 4 hertz (Hz) sampling rate of the service graphing feature, the time at
which the PRF relay opened or closed could not be defined precisely. Therefore beam-on and
beam-off latency were measured with the PRF relay status at values of 0 and 1 to establish the
range of potential latencies, as depicted in Figure 2.8. The latencies measured from the set of plots
generated were used to calculate average linear accelerator latencies and associated standard
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errors. A two-tailed independent t-test with a significance level of 0.05 was used to test the null
hypothesis that there exists no statistically significant difference in the latency of the linear
accelerator during the first and subsequent gated segments.

Figure 2.8. Plot depicting linear accelerator latencies. Beam-on latency was measured as the time
between the PRF relay status (blue) rising from 0 (dashed arrow) or reaching 1 (solid arrow) and
the dose rate (red) rising to 80% of its maximum value. Beam-off latency was measured as the
time between the PRF relay decreasing from a value of 1 (solid arrow) or reaching 0 (not shown)
and the dose rate decreasing to 20% of its maximum value.
2.3.2. End-to-End Approach
A linear relationship is expected between the displacement of a target from a reference
position and its velocity during the gating process. The rate of change between these two variables
is directly related to the magnitude of latency present in the gating system. Therefore, the end-toend latency of the gating system was computed as the slope the target’s displacement plotted as a
function of velocity.
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The linear accelerator’s EPID (iViewGT, Elekta AB, Stockholm, Sweden) was used to
capture the position of the target during the gating process, as discussed by Woods and Rong
(2015) and Snyder et al. (2017). A dynamic respiratory phantom was used to simultaneously move
the target and a reflective marker in orthogonal directions as depicted in Figure 2.9. The target was
a 3 cm diameter plastic sphere embedded in a cylindrical cedar insert, as shown in Figure 2.10.
The insert was attached to the translation stage of the phantom. The reflective marker was secured
to the chest wall platform of the phantom and monitored using the tracking camera, as shown in
Figure 2.9.
Reference images were acquired to define the position of the target when the beam was
turned on or off during the gating process under the idealized conditions of no latency present in
the gating system. Beam-on and beam-off reference images of the target were acquired with the
reflective marker positioned at the midline and the bottom threshold of the gating window since
these marker positions trigger the tracking software to send the beam-on and beam-off gating
signal, respectively. The amplitude of the chest wall platform and attached reflective marker were
manually adjusted using the dynamic phantom until the respiratory trace in the tracking software
reached the midline or bottom threshold of the gating window. Setting the reference position of
the target using the position of the reflective marker was possible because of the reproducible and
simultaneous motion of the phantom’s translation stage and chest wall platform. The linear
accelerator was operated in service mode to deliver 100 MU to the target in each reference position
using a 6 MV beam energy. The EPID was used to record these exposures using single exposure
and maximum frame averaging settings.
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Figure 2.9. Experimental setup used to quantify end-to-end latencies of the gating system.

Figure 2.10. Cross sectional view of a cylindrical insert housing a 3 cm diameter spherical target.
Experimental images were compared to the refence images to measure the displacement of
the target when driven at various velocities. The experimental images were acquired with the
phantom and gating window midline were kept in the same positions that were used to collect the
reference images. This ensured that deviations in the position of the target in the experimental
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images from its position in the reference image would be the result of the end-to-end latencies
present in the gating system. Separate procedures were employed to acquire the experimental
images used to evaluate beam-on and beam-off latency during the first and subsequent gated
segments.
For the experimental images used to evaluate beam-on latency during the first gated
segment, the EPID was initialized to record a single exposure and the linear accelerator control
system was programed to deliver 5 MU using a 6 MV beam energy. The beam was initialized
while the PRF relay was in an open state, which prevented beam delivery to begin. The dynamic
phantom was operated under software control to drive the reflective marker from the bottom to the
top of the gating window at constant velocity. Once the marker’s trace passed the midline of the
gating window the tracking software would signal to the gating interface to close the PRF relay
and begin beam delivery. During beam delivery, the EPID captured frames of the target which
were averaged together to produce a single image of the target’s travel throughout the 5 MU
exposure. Frame averaging can improve image quality by reducing image noise but can also make
it difficult to delineate the target in the image due to motion blurring, as discussed by (Yip et al.,
2014).
Experimental images used to evaluate beam-on latency during the subsequent gated
segment were acquired with linear accelerator control system programmed to deliver 8 MU. After
the first 3 MU of beam delivery, the tracking software was used to open the PRF relay, causing an
automated beam-hold. During the beam-hold, the EPID was initialized to record a single exposure.
After approximately 10 seconds of the beam being held, the reflective marker was driven from the
bottom to the top of the gating window at constant velocity, triggering beam delivery to begin. The
EPID recorded the position of the target throughout the remaining 5 MU of beam delivery.
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Multiple experimental images were acquired during the first and subsequent gated segments using
target velocities ranging from 0.5 mm per second to 8 mm per second.
For the experimental images used to evaluate beam-off latency during the first gated
segment the EPID was initialized to record a single exposure. While the beam was being delivered,
the reflective marker began inside the gating window and was driven out through the bottom
threshold of the gating window with constant velocity. The position of the target was recorded
throughout the exposure. To capture images during the subsequent gated segment, the beam was
delivered without the EPID initialized. During delivery of the first gated segment the tracking
software was used open the PRF relay, causing an automated beam-hold. During the automated
beam-hold, the EPID was initialized and the PRF relay was closed. While the second gated
segment was being delivered, the reflective marker was driven out of the gating window.
Approximately 1-5 MU were delivered during each image acquisition. Multiple experimental
images were acquired during the first and subsequent gated segments using target velocities
ranging from 1 mm per second to 48 mm per second; the images and their corresponding velocities
were saved for later analysis.
All image analysis was preformed using open-source image processing software
(Schneider et al., 2012). The images used to quantify beam-on and beam-off latency during the
first and subsequent gated segments were compiled into separate image sets using the software.
The images in each set were window and leveled with the same settings to obtain consistent image
quality. The target was contoured on the reference image and the contour was overlaid on all of
the other images in the set, as shown in Figure 2.11. The known diameter of the target was used to
calibrate the image processing software, allowing distances within each image to be measured in
mm rather than pixels.
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Beam-on displacements were measured on each experimental image from the reference
position contour to the same corresponding point on the target. The direction of motion was taken
into account when choosing the point on the reference position contour to measure from so that
the displacement resulted from the target’s travel before the beam was turned on, excluding the
target’s travel during beam delivery, as shown in Figure 2.12. For beam-off displacements, the
measurement points were chosen to ensure that the displacement would include the targets travel
during beam delivery, as shown in Figure 2.12.

Figure 2.11. Images used to quantify end-to-end beam-on latency. The direction of target travel is
specified by the arrow, shown in red. The contour of the reference position (yellow) and the target
are shown for target velocities of: (a) 0 mm per sec (reference image) (b) 1.5 mm per second (c)
4.5 mm per second (d) 7.5 mm per second.

35

Figure 2.12. Displacement between the reference position and the target. Direction of target travel
is specified by the arrow, shown in red on each image. Displacements were measured from the
reference position contour to the corresponding point on the target. (a) Beam-on displacement with
the target moving at 7.5 mm per second. (b) Beam-off displacement with the target moving at 32
mm per second.
Average displacements were calculated from the set of repeat measurements collected at
each velocity. Beam-on and beam-off displacements were plotted separately against the known
velocities of the target. A linear fit was applied to each graph using a weighted least squares fitting
routine. The slope of linear fit was used to quantify the end-to-end latency of the gating system. A
two-tailed independent t-test with a significance level of 0.05 was used to test the null hypothesis
that there exists no statistically significant difference between the gating system’s end-to-end
latencies and the summation of its individual component latencies.
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Chapter 3. Results
3.1.

Aim 1: Output and Energy Constancy
Central-axis output and beam energy were measured with and without the use of automated

beam-holds. The constancy and associated uncertainty for these dosimetric quantities were
calculated using equation (2.3.) and equation (2.4.), respectively.
3.1.1. Output Constancy
The results for central-axis output constancy are shown graphically in Figure 3.1 for each
of the linear accelerators utilized, numbered 1 through 8. Flattening filter-free (FFF) beams were
also studied using linear accelerator # 2 for the 6 MV and 10 MV beam energies, as shown in
Figure 3.1. For every beam energy investigated, output constancy was within ± 0.25% across all
linear accelerators studied. The error bars in Figure 3.1 represent the standard deviation in each
output constancy and were calculated using equation (2.4.); these standard deviations ranged from
0.021% to 0.167%.
3.1.2. Energy Constancy
In this work, TPR and PDD were used as the surrogates for photon and electron beam
energy, respectively. The results for beam energy constancy are depicted in Figure 3.2 for each of
the linear accelerators studied, numbered 1 through 8. A 6 MV and a 10 MV FFF beam were also
studied using linear accelerator # 2, as shown in Figure 3.2. For each of the photon energies
investigated, TPR constancy was within ± 0.3% across all linear accelerators studied. The error
bars in Figure 3.2 represent the standard deviation in each energy constancy and were calculated
using equation (2.4.); the standard deviations in TPR constancy ranged from 0.047% to 0.197%.
The PDD constancy for a 10 MeV electron beam was found to be within ± 0.5% across all linear
accelerators studied. The standard deviations in PDD constancy ranged from 0.068% to 0.406%.
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Figure 3.1. Central-axis output constancy for (a) 6 MV photons (b) 10 MV photons (c) 15 MV
photons (d) 10 MeV electrons.

Figure 3.2. TPR and PDD constancy for (a) 6 MV photons (b) 10 MV photons (c) 15 MV photons
(d) 10 MeV electrons.
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3.2.

Aim 2: Treatment Delivery Accuracy
A set of treatment plans from representative anatomic sites were delivered to linear

accelerators numbered 1 through 7. Each treatment plan was delivered under non-gated and gated
modes of operation. The gated mode of operation involved use the gating system under conditions
that simulated automated delivery of the DIBH technique. Analysis was performed on the
measured dose distributions obtained in each mode of operation to assess changes in the delivery
accuracy resulting from use of the gating system.
3.2.1. Analysis
The passing rates for each treatment plan using a gamma criteria of (3% dose difference,
3mm DTA) are shown in Table 3.1 and Table 3.2 for the non-gated and gated modes of operation,
respectively. All treatment deliveries in both modes of operation achieved passing rates between
94% and 100%. Additionally, the passing rates for each plan included in the set were averaged
across all linear accelerators studied. The average passing rate for each treatment plan is depicted
in Figure 3.3 and Figure 3.4 using gamma criteria of (3% dose difference, 3mm DTA) and (2%
dose difference, 1mm DTA), respectively.
The passing difference was calculated for each plan included in the set using equation
(2.5.). The average passing difference and standard error for the set of treatment plans delivered
to each linear accelerator is shown graphically in Figure 3.5. Average passing differences on these
linear accelerators were found to be within ± 0.2% and ± 0.4% using gamma criteria of (3% dose
difference, 3mm DTA) and (2% dose difference, 1mm DTA), respectively.
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Table 3.1. Gamma Passing Rates (3%, 3mm) for Non-Gated Treatment Deliveries
Linear Accelerator #

Lung
VMAT

Pancreas
VMAT

Chest Wall
VMAT

Breast
3D-CRT

Lung
SBRT

Average Passing
Rate of Set (%)

Standard
Deviation

1

99.6

99.7

99.3

96.4

100

99.0

1.5

2

99.3

100

99.6

97

100

99.2

1.3

3

99.6

97.5

99.3

94.9

100

98.3

2.1

4

100

100

99.5

98.9

100

99.7

0.5

5

97.1

99.9

95.7

98.7

100

98.3

1.9

6

98.9

99

98.1

98.9

100

99.0

0.7

7

98.7

100

98.9

98.6

100

99.2

0.7

Average Passing
Rate of Plan (%)

99.0

99.4

98.6

97.6

100.0

Standard Deviation

1.0

0.9

1.4

1.6

0.0

Table 3.2. Gamma Passing Rates (3%, 3mm) for Gated Treatment Deliveries
Linear Accelerator #

Lung
VMAT

Pancreas
VMAT

Chest Wall
VMAT

Breast
3D-CRT

Lung
SBRT

Average Passing
Rate of Set (%)

Standard
Deviation

1

99.6

99.7

99.2

96.5

100

99.0

1.4

2

99.3

99.7

99.5

96.6

100

99.0

1.4

3

99.6

97.6

99.3

94.2

100

98.1

2.4

4

100

99.9

99.3

99.3

100

99.7

0.4

5

97.1

99.9

95.5

99.2

100

98.3

2.0

6

98.9

99.1

98.3

98.5

100

99.0

0.7

7

98.9

98.8

98.8

98.8

100

99.1

0.5

Average Passing Rate
of Plan (%)

99.1

99.2

98.6

97.6

100.0

Standard Deviation

1.0

0.8

1.4

1.9

0.0
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Figure 3.3. Average gamma pass rates for treatment plans delivered using a (3%, 3mm) gamma
criteria. Non-gated deliveries are shown in grey and gated deliveries are shown in blue.

Figure 3.4. Average gamma pass rates for treatment plans delivered using a (2%, 1mm) gamma
criteria. Non-gated deliveries are shown in grey and gated deliveries are shown in blue.
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Figure 3.5. Average difference in gamma pass rates between non-gated and gated modes of
operation.
The results for the percent dose difference comparison are depicted in Figure 3.6 for linear
accelerators numbered 1 through 7. Average passing rates of 99% or greater were observed using
a passing criterion of 1%. The standard error associated with each average passing rate was used
to calculate the error bars shown in Figure 3.6.
To assess delivery reproducibility, the same lung VMAT treatment plan was delivered
three times in each mode of operation. The gamma passing rate for each delivery was calculated
using gamma analysis with gamma criteria of (3% dose difference, 3mm DTA). The average
passing rates and associated standard deviations of these deliveries are shown in Figure 3.7 for
each linear accelerator investigated. Linear accelerator #5 exhibited a standard deviation of 0.4%
in both modes of operation, which was the largest standard deviation observed for any of the linear
accelerators studied. Linear accelerators #4 and #7 were the only linear accelerators that showed
different standard deviations between non-gated and gated modes of operation. In each case, the

42

standard deviations observed in the gated mode of operation were larger by just 0.1% relative to
the non-gated mode of operation.

Figure 3.6. Percent dose difference comparison between non-gated and gated treatment deliveries
using passing criterion of 3% (grey) and 1% (blue).

Figure 3.7. Repeat delivery of a lung VMAT treatment plan. The average gamma passing rate and
standard deviation for non-gated (grey) and gated (blue) modes of operation.
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3.3.

Aim 3: Latency

3.3.1. Modular Latency Components
The modular components that contributed to the overall latency of the gating system were
each evaluated separately. The components of the respiratory motion monitoring system included
the streaming latency of the tracking camera, the sampling rate of the tracking software, and the
travel time of the gating signal from the tracking software to the gating interface. The magnitude
of these various components and their associated uncertainty are listed in Table 3.3. The total
latency of the respiratory motion monitoring system was found to be 200 ms. Additionally, the
range of linear accelerator beam-on and beam-off latencies during the first and subsequent gated
segments are tabulated in Table 3.4. A statistically significant difference in the linear accelerator’s
beam-on latency was observed t(9)=2.8, p=.02, between the first (M=2.75, SD= 0.25) and
subsequent (M=1.35, SD= 0.25) gated segments. A statistically significant difference in the linear
accelerator’s beam-off latency was not observed t(9)=0.17, p=.87, between the first (M=0.37, SD=
0.25) and subsequent (M=0.29, SD= 0.25) gated segments.
Table 3.3. Respiratory Motion Monitoring System Component Latencies
Component

Latency (Seconds)

Tracking Camera Streaming Latency

0.15 ± 0.02

Tracking Software (Time between samples)

0.052 ± 0.011

Signal Travel Time

3.7 x 10-5 ± 2 x 10-5

Total

0.20 ± 0.02
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Table 3.4. Linear Accelerator Latency
Component

Latency Range (Seconds)

Linear Accelerator Beam-on Latency

2.50 - 2.75 ± 0.25

(First Gated Segment)
Linear Accelerator Beam-on Latency

1.10 - 1.35 ± 0.25

(Subsequent Gated Segment)
Linear Accelerator Beam-off Latency

0.12 - 0.37 ± 0.25

(First Gated Segment)
Linear Accelerator Beam-off Latency

0.04 - 0.29 ± 0.25

(Subsequent Gated Segment)

3.3.2. End-to-End Latency
Plots of target displacements used to quantify end-to-end beam-on latency are shown in
Figure 3.8 for the first and subsequent gated segments. Plots used to quantify end-to-end beam-off
latency are shown Figure 3.9 for the first and subsequent gated segments. The parameters obtained
from the linear fits shown in each plot are tabulated in Table 3.5. End-to-end beam-on latency was
found to be 3.18 seconds and 1.49 seconds during the first and subsequent gated segments,
respectively. Alternatively, the end-to-end beam-off latency was found to be 0.35 seconds and 0.34
seconds during the first and subsequent gated segments, respectively. End-to-end latency
measurements are compared to the component totals in Table 3.6. The component totals shown in
Table 3.6 include the latency of the respiratory motion monitoring system and the linear
accelerator. Two separate component totals are shown for each entry in Table 3.6 to account for
the range of linear accelerator latencies measured. In each case, no statically significant differences
were found between the end-to-end latency of the gating system and its measured component
totals.
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Figure 3.8. End-to-end beam-on displacements during the (a) first gated segment (b) subsequent
gated segment.
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Figure 3.9. End-to-end beam-off displacements during the (a) first gated segment (b) subsequent
gated segment.
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Table 3.5. Displacement vs. Velocity Fitting Parameters
Beam-On

Beam-On

Beam-Off

Beam-Off

(First Segment)

(Subsequent Segment)

(First Segment)

(Subsequent Segment)

Degrees of
Freedom

13

14

31

31

Slope (Seconds)

3.18

1.49

0.35

0.34

Standard Error
of Slope

0.05

0.03

0.01

0.01

Y-Intercept (mm)

-0.51

-0.34

-0.39

-0.72

Standard Error
of Y-Intercept

0.12

0.14

0.14

0.10

R2

0.997

0.994

0.981

0.994

Chi-Squared

0.83

0.93

1.03

0.82
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Table 3.6. Comparison of End-to-End Latency and Component Totals
Component Total

End-to-End

t-value

p

2.70 ± 0.25

3.18 ± 0.05

t(df=13)=1.59 .14

2.95 ± 0.25

3.18 ± 0.05

t(df=13)=0.76 .46

1.30 ± 0.25

1.49 ± 0.03

t(df=14)=0.67 .51

1.55 ± 0.25

1.49 ± 0.03

t(df=14)=0.21 .83

0.33 ± 0.25

0.35 ± 0.01

t(df=31)=0.10 .92

0.58 ± 0.25

0.35 ± 0.01

t(df=31)=0.87 .39

0.24 ± 0.25

0.34 ± 0.01

t(df=31)=0.40 .69

0.49 ± 0.25

0.34 ± 0.01

t(df=31)=0.56 .58

Beam-On Latency (Seconds)
First Gated Segment

Subsequent Gated Segment

Beam-Off Latency (Seconds)
First Gated Segment

Subsequent Gated Segment
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Chapter 4. Discussion
4.1.

Aim 1: Output and Energy Constancy
The output and energy constancies reported in this work were all within ± 0.5%, which was

generally consistent with the findings of Saito et al. (2018),who reported constancies within 0.5%
when the beam-on durations were 2 seconds or greater. They also performed these measurements
with gating cycles consisting of 1.1 second beam-on durations followed by 2 second beam-holds
and reported larger output constancies approaching 1% for these deliveries, but an increase in
output constancy is expected when utilizing low duty cycles during gated delivery (Freislederer et
al., 2015).
To our knowledge, this is the first work to assess the output and energy constancy of an
electron beam resulting from automated beam gating. The output constancies and associated
uncertainties observed using electrons were similar to those observed using photons. In contrast,
the uncertainties associated with electron PDD constancy tended to be larger than those observed
for photon TPR measurements. This may be attributed to the steeper dose falloff at depth that
electrons exhibit relative to photons which could result in larger variations in the repeated
measurements of electron PDD compared to photon TPR.
Output and energy constancy were evaluated across 8 beam-matched linear accelerators
using a variety of beam energies. This allowed for the intercomparison of gating performance
across linear accelerators and beam energies. Ultimately, the results reported in this work support
the hypothesis that the gating system can achieve output and energy constancy within 2% during
automated deliveries that are representative of the DIBH technique.
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4.2.

Aim 2: Treatment Delivery Accuracy
In this work, gamma analysis was used to evaluate the agreement between the measured

and planned dose distributions for each treatment delivery. The passing difference represented the
change in gamma passing rates between non-gated and gated modes of operation. This metric
could be misleading if the passing rates for both non-gated and gated treatment deliveries were
similar but demonstrated poor agreement to the planned dose distribution. This situation would
yield a small passing difference, even though the treatment plan was not accurately delivered in
each mode of operation. This was not a concern of this work because of the relatively high gamma
passing rates achieved in each mode of operation. Our findings support the hypothesis that the
gating system could facilitate gated treatment deliveries with passing differences within 2% on
average.
Delivery accuracy was also evaluated using the percent dose difference comparison. While
the passing difference compared the two modes of operation indirectly using the planned dose
distribution, the percent dose difference comparison allowed for deliveries in each mode of
operation to be compared directly to one another. Noto et al. (2014) reported passing rates of 100%
using a percent dose difference comparison with a 1% passing criterion. However, the manual
beam-holds that were employed in their work may not adequately replicate the delivery
characteristics encountered with use of an automatic gating interface. In our work, average passing
rates ranged from 99% to 100% depending on the linear accelerator being studied. These results
demonstrate a high level of agreement between treatments delivered in the non-gated and gated
modes of operation.
A single lung VMAT treatment plan was delivered three times in each mode of operation.
The standard deviation in the gamma passing rates of these repeat deliveries was used to assess
delivery reproducibility. The largest standard deviation observed was just 0.4%, demonstrating
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that in each mode of operation, the treatment plan was able to be delivered in a reproducible
manner. Additionally, the differences in the standard deviations between modes of operation
suggest that the gating system could facilitate automated delivery of the DIBH technique with a
level of reproducibility that is comparable to the non-gated mode of operation.
4.3.

Aim 3: Latency

4.3.1. Modular Latency Components
This work presented a modular approach to quantify the latencies of a gating system. One
of the benefits of a modular approach is that relevant latencies can be substituted for gating systems
that are composed of different components than the ones studied in this work. Of the component
latencies reported for the respiratory motion monitoring system, the latency of the tracking camera
was greatest. The total latency of the respiratory motion monitoring system, including the latency
of the tracking camera, was found to be 200 ms. This finding was consistent with the latency of
other respiratory motion monitoring systems that utilize optical tracking as discussed by
Freislederer et al. (2015), who reported values ranging from 162 to 262 ms.
The other major contributor to the overall latency of the gating system was the latency of
the linear accelerator (Freislederer et al., 2015). In this work, the beam-on or beam-off latency of
the linear accelerator was defined as the time delay between the PRF relay changing to the
appropriate state and the dose rate of the linear accelerator rising to 80% of its maximum value or
decreasing to 20% of its maximum value, respectively. During the first and subsequent gated
segments, the beam-on latency of the linear accelerator was found to be larger than its beam-off
latency. This is expected, because beam startup involves magnetron tuning and electron gun rampup whereas initiating automated beam-holds simply require interrupting the linear accelerator’s
digital PRF interlock (Saito et al., 2018). Based on our results, the respiratory motion monitoring
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system is the major contributor to the gating system’s beam-off latency and the linear accelerator
is the major contributor to the gating system’s beam-on latency, which is consistent with the
findings of Saito et al. (2018).
A statistically significant difference in the linear accelerator’s beam-on latency was
observed between the first and subsequent gated segments. Saito et al. (2018) attributed this to the
electron gun remaining at its operating level during beam-holds, allowing quicker start up during
the subsequent gated segments compared to the first segment of gated delivery. The electron gunhold time is an adjustable parameter on certain linear accelerators (Elekta Oncology Systems,
Stockholm, Sweden) that determines the amount of time that the electron gun will remain at its
operating level following a beam-hold. Previous work has shown that when the duration of a beamhold exceeds the electron gun-hold time, the gun will enter a stand-by state which requires
additional ramp-up time to return to its operating level before beam delivery can resume (Cui et
al., 2014). In this work, the beam-holds that occurred prior to the subsequent gated segment were
purposefully chosen to exceed the maximal gun-hold time achievable on the linear accelerator of
6.5 seconds. Even with the additional ramp-up time resulting from the electron gun entering a
stand-by state, a statistically significant difference in beam-on latency was still observed between
the first and subsequent gated segments. Therefore, the observed difference in beam-on latency is
likely the result of linear accelerator startup processes that only occur during the first gated
segment as well as quicker electron gun ramp-up times that occur prior to the subsequent gated
segment compared to the first gated segment. No statistically significant difference in the linear
accelerator’s beam-off latency was observed between the first and subsequent gated segments. To
our knowledge, this is the first study that has quantified the latency of the linear accelerator during
the first and subsequent gated segments using this gating interface.

53

4.3.2. End-to-End Latency
Negative offset values were observed for each of the linear fits performed. Ideally each
offset should be zero, because at zero velocity there should be no displacement of the target from
the reference position. This suggests a systematic error in our experimental methodology, which
could have resulted from incorrectly setting the marker surrogate at the appropriate gating
thresholds when establishing the reference position. However, this type of systematic error is not
expected to impact the latencies reported in this work because the resulting offsets would not affect
the slopes of the linear fits performed. Woods and Rong (2015) performed similar measurements
and also observed negative offset values, which they discussed was likely the result of
measurement uncertainty and finite pixel size. In our work, the observed offsets were within the
length of a single pixel used to track the marker surrogate.
The end-to-end beam-on latency of the gating system was found to be 3.18 seconds and
1.49 seconds for the first and subsequent gated segments, respectively. Others in the literature have
reported considerably smaller beam-on latencies than those reported in this work (Saito et al.,
2018; Snyder et al., 2017). However, these works were evaluating the latencies associated with
free-breathe respiratory gating, which utilizes shorter beam-holds than those encountered with the
DIBH technique. Therefore, the linear accelerator’s electron gun was able to remain at its operating
level throughout each beam-hold, which is likely the reason for the considerably shorter beam-on
latencies that these works have reported. The end-to-end beam-on latency reported in this work
for the subsequent gated segment of 1.49 seconds was consistent with the findings of Cui et al.
(2014), who utilized a similar respiratory motion monitoring system. They reported beam-on
latencies of 1.38, 1.44, and 1.49 seconds using a continuously variable dose rate and beam-holds
that exceeded the electron gun-hold time, both of which were conditions utilized in this work.
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For beam-off latency, measured displacements were found to deviate from the linear fit at
high target velocities. This is likely the result of the target passing the gating threshold before it
accurately reached its programmed velocity. To assess the impact that these data points had on the
reported beam-off latencies, the linear fits were also performed without data from target velocities
greater than 24 mm per second. For both the first and subsequent gated segments, excluding these
data points changed the resultant latency values by less than 30 ms. Therefore, the inclusion of
these high velocity measurements did not impact the major findings reported in this work. End-toend beam-off latency was found to be 350 ms and 340 ms for the first and subsequent gated
segments, respectively, which exceeded the hypothesized value of 300 ms. Moving forward, the
tracking software could be adjusted to compensate for the gating system’s beam-off latency by
signaling to the gating interface to initiate a beam-hold prior to the surrogate exiting the gating
window. However, this adjustment could prematurely terminate the breath-hold cycle if the patient
trended toward, but was able to remain within, the gating window. Another option would be to
replace the tracking camera with one that has less streaming latency, as the tracking camera’s
streaming latency was found to be the largest contributor to the gating system’s beam-off latency.
In every case tested, no statistically significant difference was observed between end-toend latency derived from the linear fit and the summation of the gating system’s measured
component latencies. This agreement lends credibility to both the modular approach and the
methods used for end-to-end measurements. The methods described in this work to quantify
latency are generalizable to other respiratory gating systems that utilize this gating interface.
However, some degree of variability in the latencies measured for other systems are expected.
Within the control system of the linear accelerator, several parameters can be adjusted to alter the
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temporal characteristics of gated delivery, particularly with regards to beam-on latency (Cui et al.,
2014; Snyder et al., 2017).
It is expected that the beam-on latencies reported in this work could be reduced by altering
several parameters within the control system of the linear accelerator. However, there is some
tradeoff between the time it takes for the linear accelerator to begin producing radiation pulses and
the dosimetric stability of those pulses during beam startup. A potential consequence of altering
the control system configuration of the linear accelerator to dimmish the gating system’s beam-on
latency is dosimetric degradation, which was not studied in this particular work. For our
application, we didn’t need to decrease the beam-on latency of the gating system given the duration
of the breath-hold intervals used clinically. For systems that are intended for free-breathe gating
applications, optimizing the control system configuration of the linear accelerator to minimize the
gating system’s beam-on latency may be necessary.
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Chapter 5. Summary and Conclusions
5.1.

Limitations and Future Work
One of the limitations of this work is the different number of monitor units that were

delivered in the non-gated and gated modes of operation to measure central-axis output and energy
constancy. Measurements collected in the gated mode of operation were more likely to be affected
by electrometer leakage because of the longer delivery times utilized in the gated mode of
operation compared to the non-gated mode of operation. While it is expected that the contribution
of the electrometer leakage on the measured constancies was negligible, future work could address
this by utilizing comparable delivery times for measurements made in each mode of operation.
Another limitation is the use of measured displacements to quantify end-to-end latencies,
which relied on visual identification to define the appropriate edge of the target in each image.
Motion blurring and poor image quality at MV beam energies makes this method susceptible to
error. Additionally, the service graphing feature provided a convenient method for quantifying the
latency of the linear accelerator, but its sampling frequency limited the achievable precision of this
technique. Future work could evaluate the temporal characteristics of the respiratory gating system
using methods described by Wiersma et al. (2016), which would provide higher temporal
resolution when measuring beam-on and beam-off latencies.
It was shown that during automated delivery, there was a statistically significant difference
in the linear accelerator’s beam-on latency between the first and subsequent gated segments. Often
times, treatments involving the DIBH technique are delivered by manually activating and
interrupting the radiation beam at the appropriate times. Future work is needed to determine if the
increased beam-on latency observed during the first gated segment occurs after each manual beamhold. If so, automated delivery of DIBH treatments using this gating interface may increase the
delivery efficiency compared to manual delivery. Regardless, the differences in beam-on latency
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observed in this work between the first and subsequent gated segments are not clinically
meaningful for gating systems intended for DIBH applications, given the duration of the breathhold intervals used clinically. Future work is needed to investigate these beam-on latencies when
the linear accelerator control system is optimized for free-breathe respiratory gating, as latency
differences between the first and subsequent gated segments could have a clinically meaningful
impact for this type of application.
5.2.

Conclusions
This work characterized the performance of a respiratory gating system both dosimetrically

and temporally. The gating system utilized an automatic gating interface to connect a markerbased respiratory motion monitoring system to the linear accelerator control system. To our
knowledge, this is the first work to extensively validate this automatic gating interface for use with
an abdominal marker-based optical tracking system. Dosimetric characteristics associated with use
of the gating system were evaluated across multiple linear accelerators which allowed for
intercomparison of its gating performance. It was shown that the gating system can achieve the
desired dosimetric operating characteristics during automated delivery of the DIBH technique,
which included output and energy constancy within 2% and an average decrease in gamma passing
rates between the non-gated and gated modes of operation that was less than 2%. The hypothesis
of this work was not fully supported, as the gating system was not able to achieve all of the desired
operating characteristics, in particular, the system’s beam-off latency was found to exceed 300 ms.
However, now that a baseline has been established, adjustments can be made to compensate for
these measured delays. The methodology presented in this work can be used by others to validate
the dosimetric and temporal characteristics of their own respiratory gating systems that utilize this
automatic gating interface.
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